Drug Trial Radar · NCT06134648
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
646
Actual
Start
Nov 1, 2023
Primary completion
Feb 27, 2026
Study completion Feb 27, 2026
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.
Conditions
- Respiratory Syncytial Virus Infection
- Healthy Volunteers
- Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose LBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
RSV/hMPV vaccine candidate Dose ABiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
RSV/hMPV vaccine candidate Dose BBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
PlaceboBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of unsolicited systemic immediate adverse events (AEs)Time frame: Within 30 minutes after primary vaccination
- Presence of solicited injection site or systemic reactionsTime frame: Within 7 days after primary vaccination
- Presence of unsolicited AEsTime frame: Within 28 days after vaccination
- Presence of medically attended adverse events (MAAEs)Time frame: Up to 6 months after primary injection
- Presence of serious adverse events (SAEs)Time frame: Up to 6 months after primary injection
- Presence of adverse events of special interest (AESIs)Time frame: Up to 6 months after primary injection
- Presence of related SAEsTime frame: Throughout study (approximately 24 months)
- Presence of related AESIsTime frame: Throughout study (approximately 24 months)
- Presence of fatal SAEsTime frame: Throughout study (approximately 24 months)
- Presence of out-of-range biological test resultsTime frame: Within 7 days after vaccination
- RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- primary vaccination (D29) in Phase IIa (Main/Booster Cohort)Time frame: Day 1 and Day 29
- hMPV serum nAb titers at pre-vaccination (D01), 28 days post-primary vaccination (D29) in Phase IIa (Main/Booster Cohort)Time frame: Day 1 and Day 29
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Collaborative Neuroscience Research Site Number : 8400017
Los Alamitos, California
Matrix Clinical Research Site Number : 8400011
Los Angeles, California
Peninsula Research Associates Site Number : 8400001
Rolling Hills Estates, California
Suncoast Research Associates, LLC Site Number : 8400002
Miami, Florida
AMR Chicago, Oakbrook Terrace Site Number : 8400019
Oakbrook Terrace, Illinois
Velocity Clinical Research, Sioux City Site Number : 8400012
Sioux City, Iowa
AMR Lexington Site Number : 8400008
Lexington, Kentucky
AMR Kansas City Site Number : 8400014
Kansas City, Missouri
AMR Knoxville Site Number : 8400010
Knoxville, Tennessee
DM Clinical Research - Tomball Site Number : 8400004
Tomball, Texas
Investigational Site Number : 6300002
Guayama, Puerto Rico
Investigational Site Number : 6300001
San Juan, Puerto Rico
Investigational Site Number : 6300003
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.